[go: up one dir, main page]

ECSP11011165A - Compuesto heterocíclico y uso del mismo - Google Patents

Compuesto heterocíclico y uso del mismo

Info

Publication number
ECSP11011165A
ECSP11011165A EC2011011165A ECSP11011165A ECSP11011165A EC SP11011165 A ECSP11011165 A EC SP11011165A EC 2011011165 A EC2011011165 A EC 2011011165A EC SP11011165 A ECSP11011165 A EC SP11011165A EC SP11011165 A ECSP11011165 A EC SP11011165A
Authority
EC
Ecuador
Prior art keywords
same
heterocyclic compound
raf
symbol
salt
Prior art date
Application number
EC2011011165A
Other languages
English (en)
Inventor
Masanori Okaniwa
Terufumi Takagi
Masaaki Hirose
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011165(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of ECSP11011165A publication Critical patent/ECSP11011165A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporciona un derivado heterocíclico condensado que muestra una fuerte actividad inhibitoria de Raf. Un compuesto representado por la fórmula en donde cada símbolo es según lo definido en la presente especificación, o una sal de la misma.
EC2011011165A 2008-12-02 2011-06-29 Compuesto heterocíclico y uso del mismo ECSP11011165A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008307581 2008-12-02
JP2009125256 2009-05-25

Publications (1)

Publication Number Publication Date
ECSP11011165A true ECSP11011165A (es) 2011-07-29

Family

ID=42026212

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011165A ECSP11011165A (es) 2008-12-02 2011-06-29 Compuesto heterocíclico y uso del mismo

Country Status (40)

Country Link
US (2) US8143258B2 (es)
EP (1) EP2358689B9 (es)
JP (1) JP5640014B2 (es)
KR (1) KR101639092B1 (es)
CN (1) CN102300854B (es)
AR (1) AR074435A1 (es)
AU (1) AU2009323274B2 (es)
BR (1) BRPI0922109A2 (es)
CA (1) CA2745144C (es)
CL (1) CL2011001299A1 (es)
CO (1) CO6400140A2 (es)
CR (1) CR20110366A (es)
CY (1) CY1117178T1 (es)
DK (1) DK2358689T5 (es)
DO (1) DOP2011000165A (es)
EA (1) EA019447B1 (es)
EC (1) ECSP11011165A (es)
ES (1) ES2557304T3 (es)
GE (1) GEP20146003B (es)
HR (1) HRP20151370T1 (es)
HU (1) HUE026491T4 (es)
IL (1) IL213184A0 (es)
JO (1) JO3101B1 (es)
MA (1) MA32911B1 (es)
ME (1) ME02331B (es)
MX (1) MX2011005836A (es)
MY (1) MY150989A (es)
NZ (1) NZ593759A (es)
PE (1) PE20110588A1 (es)
PL (1) PL2358689T3 (es)
PT (1) PT2358689E (es)
RS (1) RS54370B9 (es)
SG (1) SG171426A1 (es)
SI (1) SI2358689T1 (es)
SM (1) SMT201500316B (es)
TN (1) TN2011000280A1 (es)
TW (1) TWI436987B (es)
UY (1) UY32281A (es)
WO (1) WO2010064722A1 (es)
ZA (1) ZA201104659B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2162445B1 (en) * 2007-06-05 2013-11-27 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
US8324395B2 (en) * 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8445509B2 (en) * 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
EP2830664A1 (en) * 2012-03-30 2015-02-04 Takeda Pharmaceutical Company Limited Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma
CA3139033A1 (en) 2012-08-22 2014-02-27 Cornell University Methods for inhibiting fascin
US9670231B2 (en) 2013-06-28 2017-06-06 Beigene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
AU2014301816B2 (en) 2013-06-28 2017-06-01 Beigene, Ltd. Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors
CN103408541B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途
CN103435572B (zh) * 2013-07-16 2015-02-04 浙江医药高等专科学校 噻唑并环己烷类化合物、其制备方法和抗肿瘤用途
CN103382190B (zh) * 2013-07-16 2015-01-14 浙江医药高等专科学校 一类噻唑并环己烷类化合物、其制备方法和用途
CN103435573B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 苄基取代的噻唑并环己烷类化合物、其制备方法和用途
CN106232583B (zh) 2014-02-20 2020-04-24 康奈尔大学 用于抑制肌成束蛋白的化合物和方法
CA2954764A1 (en) 2014-07-15 2016-01-21 Ontario Institute For Cancer Research Methods and devices for predicting anthracycline treatment efficacy
JP2018502087A (ja) * 2014-12-23 2018-01-25 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｒａｆ阻害剤及びタキサンの組み合わせ
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
WO2017165491A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
MA44483A (fr) 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
CN109053630B (zh) * 2018-08-22 2022-04-01 中国人民解放军第二军医大学 一种苯并噻唑类衍生物及其用途
US20230148448A9 (en) * 2018-11-07 2023-05-11 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020232445A1 (en) * 2019-05-16 2020-11-19 The Regents Of The University Of California Modulators of pyrimidine nucleotide biosynthetic pathways
CA3181537A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN112094248B (zh) * 2020-09-17 2023-05-12 中国人民解放军海军军医大学 一种取代苯并噻唑类化合物及其用途
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
JP2024540292A (ja) 2021-11-09 2024-10-31 エイジャックス セラピューティクス， インコーポレイテッド Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
CN115724837B (zh) * 2022-10-26 2024-07-23 中国人民解放军海军军医大学 一种抑制程序性细胞坏死的苯并噻唑衍生物及其应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2399026A (en) * 1941-02-06 1946-04-23 Chem Ind Basel Amides of 2-aminoarylenethiazoles
US4096264A (en) 1975-12-09 1978-06-20 Merck & Co., Inc. Certain substituted imidazo [1,2-a] pyridines
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
NZ503432A (en) 1997-09-26 2002-11-26 Zentaris Gmbh Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
ATE460398T1 (de) * 1999-01-13 2010-03-15 Bayer Healthcare Llc Verwendung von omega-carboxyaryl-substituierten diphenylharnstoffen als raf-kinase-inhibitoren
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
IL144144A0 (en) 1999-01-13 2002-05-23 Bayer Ag Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AU771504B2 (en) * 1999-01-22 2004-03-25 Kyowa Hakko Kirin Co., Ltd. Quinoline derivatives and quinazoline derivatives
AU5570600A (en) 1999-07-01 2001-01-22 Ajinomoto Co., Inc. Heterocyclic compounds and medicinal use thereof
CA2389767C (en) 1999-11-05 2010-03-23 Laurent Francois Andre Hennequin Quinazoline derivatives as vegf inhibitors
SK12712002A3 (sk) 2000-02-07 2003-02-04 Abbott Gmbh & Co. Kg Deriváty 2-benzotiazolylmočoviny a ich použitie ako inhibítorov proteínkináz
CO5280092A1 (es) 2000-02-15 2003-05-30 Sugen Inc Indolinas susutituidas con pirroles inhibidoras de proteinquinasas
ATE266022T1 (de) 2000-03-06 2004-05-15 Smithkline Beecham Plc Imidazol derivate als raf kinase inhibitoren
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
PT1303272E (pt) 2000-06-21 2008-04-14 Hoffmann La Roche Derivados de benzotiazole
CN1471523A (zh) 2000-09-21 2004-01-28 ʷ 咪唑类棉子糖激酶抑制剂
CN1308310C (zh) 2000-10-20 2007-04-04 卫材R&D管理有限公司 含氮芳环衍生物
AU2002232439A1 (en) * 2000-11-29 2002-06-11 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
GB0121494D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
ATE403653T1 (de) 2001-09-05 2008-08-15 Smithkline Beecham Plc Pyridin-substituierte furanderivate als raf- kinase inhibitoren
EP1432703A1 (en) 2001-09-05 2004-06-30 Smithkline Beecham Plc Heterocycle-carboxamide derivatives as raf kinase inhibitors
AU2003220970A1 (en) 2002-03-01 2003-09-16 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
EP1499311B1 (en) * 2002-03-29 2009-11-04 Novartis Vaccines and Diagnostics, Inc. Substituted benzazoles and use thereof as raf kinase inhibitors
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
US7378233B2 (en) * 2003-04-12 2008-05-27 The Johns Hopkins University BRAF mutation T1796A in thyroid cancers
DE10334663A1 (de) * 2003-07-30 2005-03-10 Merck Patent Gmbh Harnstoffderivate
DE10337942A1 (de) 2003-08-18 2005-03-17 Merck Patent Gmbh Aminobenzimidazolderivate
WO2005037273A1 (en) 2003-10-16 2005-04-28 Chiron Corporation Substituted benzazoles and use thereof as inhibitors of raf kinase
EP1751124A4 (en) 2004-05-07 2010-04-14 Exelixis Inc RAF MODULATORS AND METHODS OF USE
MX2007001155A (es) 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
KR20060079098A (ko) 2004-12-31 2006-07-05 주식회사 엘지생명과학 신규한([1,3]티아졸로[5,4-ｂ]피리딘-2-일)-2-카르복사마이드유도체
WO2006076376A1 (en) 2005-01-11 2006-07-20 Medicinova, Inc. Topical treatment of solid tumors and ocular neovascularization
CN101106990B (zh) * 2005-01-26 2010-12-08 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
JP4033409B1 (ja) 2005-07-11 2008-01-16 田辺三菱製薬株式会社 オキシム誘導体及びその製法
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
WO2007058482A1 (en) 2005-11-16 2007-05-24 Lg Life Sciences, Ltd. Novel inhibitors of protein kinase
DK2010528T3 (en) 2006-04-19 2018-01-15 Novartis Ag 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods for Inhibiting CSF-1R Signaling
PE20080538A1 (es) 2006-08-04 2008-06-18 Takeda Pharmaceutical Derivado heterociclico fusionado y su uso
EP2058309A4 (en) 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
JP4328820B2 (ja) 2007-01-10 2009-09-09 田辺三菱製薬株式会社 医薬組成物
WO2008084873A1 (ja) 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation オキシム誘導体
CN101260106A (zh) * 2007-03-06 2008-09-10 中国药科大学 Raf激酶抑制剂及其制备方法和用途
ATE540676T1 (de) 2007-04-13 2012-01-15 Rikshospitalet Radiumhospitalet Hf Egfr-inhibitoren zur behandlung und diagnose von metastasierendem prostatakrebs
US20110091377A1 (en) 2007-05-11 2011-04-21 The Johns Hopkins University Biomarkers for melanoma
AU2008256922B2 (en) 2007-05-23 2011-07-28 Novartis Ag Raf inhibitors for the treatment of thyroid cancer
EP2162445B1 (en) 2007-06-05 2013-11-27 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
JP2008307581A (ja) 2007-06-15 2008-12-25 Sanyo Special Steel Co Ltd 管材の洗浄装置
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JP5350247B2 (ja) 2007-08-29 2013-11-27 武田薬品工業株式会社 複素環化合物およびその用途
WO2009028655A1 (ja) 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
JP2009125256A (ja) 2007-11-22 2009-06-11 Kandado:Kk 安眠枕
CN101220024A (zh) * 2007-12-11 2008-07-16 杜晓敏 一组抑制激酶的抗癌化合物
WO2009099991A2 (en) 2008-01-31 2009-08-13 The Brigham And Women's Hospital, Inc. Treatment of cancer
US20090275546A1 (en) * 2008-04-10 2009-11-05 Istituto Superiore Di Sanita Diagnostic tests and personalized treatment regimes for cancer stem cells
US8445509B2 (en) 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof

Also Published As

Publication number Publication date
US8497274B2 (en) 2013-07-30
PL2358689T3 (pl) 2016-03-31
CR20110366A (es) 2011-08-29
AU2009323274A1 (en) 2011-07-07
KR20110091039A (ko) 2011-08-10
HK1161236A1 (zh) 2012-08-24
US20120214855A1 (en) 2012-08-23
GEP20146003B (en) 2014-01-10
CN102300854B (zh) 2015-01-07
EP2358689A1 (en) 2011-08-24
EP2358689B9 (en) 2016-08-03
ES2557304T3 (es) 2016-01-25
EA019447B1 (ru) 2014-03-31
AU2009323274B2 (en) 2015-09-17
CL2011001299A1 (es) 2012-01-13
AR074435A1 (es) 2011-01-19
US20100216810A1 (en) 2010-08-26
HUE026491T2 (en) 2016-06-28
US8143258B2 (en) 2012-03-27
RS54370B9 (sr) 2020-01-31
HRP20151370T1 (hr) 2016-01-15
IL213184A0 (en) 2011-07-31
CO6400140A2 (es) 2012-03-15
CN102300854A (zh) 2011-12-28
SI2358689T1 (sl) 2016-01-29
PE20110588A1 (es) 2011-09-08
JO3101B1 (ar) 2017-09-20
HUE026491T4 (en) 2017-07-28
CA2745144C (en) 2017-10-03
CA2745144A1 (en) 2010-06-10
BRPI0922109A2 (pt) 2020-09-01
NZ593759A (en) 2012-07-27
MA32911B1 (fr) 2011-12-01
CY1117178T1 (el) 2017-04-05
KR101639092B1 (ko) 2016-07-12
JP5640014B2 (ja) 2014-12-10
MX2011005836A (es) 2011-06-17
EA201170735A1 (ru) 2011-12-30
TWI436987B (zh) 2014-05-11
ZA201104659B (en) 2012-08-29
DK2358689T5 (en) 2016-10-10
ME02331B (me) 2016-04-28
RS54370B1 (en) 2016-04-28
UY32281A (es) 2010-06-30
JP2012510467A (ja) 2012-05-10
SMT201500316B (it) 2016-01-08
SG171426A1 (en) 2011-07-28
TN2011000280A1 (en) 2012-12-17
EP2358689B1 (en) 2015-09-30
TW201024272A (en) 2010-07-01
DOP2011000165A (es) 2011-06-30
DK2358689T3 (en) 2015-12-14
MY150989A (en) 2014-03-31
WO2010064722A1 (en) 2010-06-10
PT2358689E (pt) 2015-12-30

Similar Documents

Publication Publication Date Title
ECSP11011165A (es) Compuesto heterocíclico y uso del mismo
DOP2009000227A (es) Derivados de aril isoxazolina insecticidas
CO6361854A2 (es) Tiazoles sustituidos con heterociclilo como agentes fitosanitarios
CR20120277A (es) Una forma cristalina y amorfa de genz 112638 hemitartrato como inhibidores de glucosilceramida sintasa
DOP2015000251A (es) Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina
DE602008000754D1 (de) Tropanverbindungen
CR20140537A (es) Compuesto heterocíclico nitrogenado
CO6480909A2 (es) Derivados de tiazolilpiperidina como fungicidas.
BRPI0907435A8 (pt) derivados de 5-flúor pirimidina
EA200801630A1 (ru) Соединения пиперазина с гербицидным действием
CR20110635A (es) Quinazolinas sustituidas como fungicidas
AR083234A1 (es) Composicion pesticida y su uso
WO2009028655A1 (ja) 複素環化合物およびその用途
WO2009025358A1 (ja) 複素環化合物およびその用途
BRPI0808172A2 (pt) Compostos heterocíclicos, composições compreendendo-os e métodos de seu uso.
UY30087A1 (es) Piperazinas y piperidinas como potenciadoras de mglur5
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares
BR112013032758A2 (pt) derivados de n-oxi-pirazolo-triazepino-diona
ECSP10010626A (es) Derivados de iminopiridina y su uso
CL2013002027A1 (es) Formas cristalinas i y ii de (r)-1-etil-3-[6-fluoro-5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7(tetrahidrofuran-2-il)-1h-benzimidazol-2-il]urea, inhibidor de girasa; composicion farmeceutica; y uso poara tratar o reducir una infeccion bacteriana.
BR112014012983A2 (pt) derivados de pirrol
ECSP13012535A (es) Compuesto heterocíclico y sus usos
EA200900780A1 (ru) Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства
UY32042A (es) Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90
UY30235A1 (es) Inhibidores de la adenilato ciclasa soluble